224 patients over the age of 50 with a pertrochanteric hip fracture who had undergone fixation were randomized to 26 weeks of daily subcutaneous teriparatide 20ug or weekly oral risedronate 35mg. The purpose of this study was to compare measures of functional and clinical outcome, as well as safety outcomes and fracture healing over a 26-week follow-up. Results demonstrated significantly better Timed Up-and-Go results and pain scores during the TUG test up to 12 weeks and 18 weeks, respectively, in the teriparatide group compared to the risedronate group. By 26 weeks, differences between groups were non-significant. Hyperuricemia at 6 weeks and hypercalcemia at 26 weeks was significantly more frequent in the teriparatide group compared to the risedronate group. There were no significant differences in radiographic healing, mechanical failure of the implant, loss of reduction and nonunion between groups.